NeoGenomics, Inc. (NEO) Stock Analysis

NeoGenomics, Inc. (NEO) Stock Analysis — AI Research | MarketCI

NEO

Market Closed

NeoGenomics, Inc.

NASDAQHealthcare Medical - Diagnostics & Research

2.50K employees

CEO: Anthony Zook

Founded: 2004

$13.89

+$0.00(+NaN%)

Market Cap

361.73M

Beta

1.74

52W Range

N/A

Dividend Yield

2.88%

Overview Forecasts Fundamental Market Sentiment Valuation Ownership

NEO Price Chart

Historical price performance

Loading MCI price data...

MarketCI Investment Signals

AI-synthesized investment signal for NEO built from valuation, fundamentals, sentiment, and risk models

Investment Signal

Strong Sell

Pass %

28.57%

Score

2/7

Fair Value Estimate

Cash flow analysis • Multiple methods

-$89.12

AI Price Target

Machine learning • Price prediction

$13.48

Market Sentiment

News & social media analysis

0.00

Value Investor Price

Classic value analysis

$0.00

Financial Health

Bankruptcy risk assessment

0.44

Quality Score

Financial strength rating

4.00

AI Investment Grade

Deep analysis of filings & news

65.00

Key Investment Highlights

Important factors affecting NEO investment thesis

Due Diligence Analysis

Investment criteria assessment and scoring

Overall Assessment

57.50% Good

Conditions Met

23.00/40.00

Due Diligence Score

57.50%

Due Diligence Conditions

Investment analysis conditions and results


	Pass
	Fail
	Pass
	Pass
	Pass
	Pass

Showing 1 to 6 of 46 conditions